[{"id":"40c5a9dd-b0cf-48c4-bf22-51d4452040b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448718","created_at":"2021-01-18T17:00:17.468Z","updated_at":"2025-02-25T14:58:45.009Z","phase":"Phase 2","brief_title":"Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","source_id_and_acronym":"NCT03448718","lead_sponsor":"Matthew Galsky","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/17/2018","start_date":" 04/17/2018","primary_txt":" Primary completion: 07/14/2021","primary_completion_date":" 07/14/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2023-11-22"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"}]